



## Mithra Announces Estelle® Launch in Belgium

Liege, Belgium, 21 October 2021 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, is very pleased to announce that its novel combined oral contraceptive Estelle® is now available in Belgium. The product is marketed in Belgium by Richter under the brand name Drovelis® and by Ceres Pharma under the brand name Lydisilka®.

Developed by Mithra, Estelle® is composed of 15 mg estetrol (E4), a unique native estrogen and 3 mg drospirenone. E4 is produced by the human fetus, passing the maternal blood at relatively high levels during pregnancy, that is now synthesised from a plant source. In two phase III clinical studies conducted in 3,725 women, Estelle® showed positive results for primary efficacy and safety endpoints and achieved positive secondary endpoints including good bleeding profile, cycle control, and tolerability.

Approved by the European Medicines Agency (EMA) in May 2021, Mithra's product is the first new estrogen in a combined oral contraceptive in over half a century. Richter already launched the product in several European countries, like Germany, Austria, Poland, Hungary, Slovakia and now Belgium. Currently, the total European contraceptives market is valued at approximately EUR 1.6 billion annually<sup>1</sup>.

Leon Van Rompay, CEO Mithra Women's Health, commented: *"After the successful launch of Estelle® in the United States, Canada and several European countries, we are extremely pleased to see the first estetrol-based product launched in our country where the project started and was successfully developed. Our teams are particularly proud to see the result of so many years of research and development now available to patients. Finally, Mithra can provide a real alternative in contraception to all women."*

Professor Jean-Michel Foidart, Permanent Secretary of the Royal Academy of Medicine of Belgium and co-founder of Mithra, added: *"We've been working on estetrol, a native hormone produced by the human body during pregnancy, for many years to develop and bring a new generation contraceptive pill with a clear benefit/risk profile aiming to improve women's quality of life. This product promises to be a major breakthrough in a space where there hasn't been any innovation in decades."*

\*\*\*\*\*

**For more information, please contact:**

Benoît Mathieu (IRO) : +32 473 35 80 18 - [investorrelations@mithra.com](mailto:investorrelations@mithra.com)  
Maud Vanderthommen (Press) : +32 473 58 61 04 – [press@mithra.com](mailto:press@mithra.com)

---

<sup>1</sup> IQVIA 2021

## About Mithra

*Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women health and beyond. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. [www.mithra.com](http://www.mithra.com)*

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

---



News  
Alerts

Subscribe to our mailing list on [investors.mithra.com](http://investors.mithra.com) to receive our press releases by email or follow us on our social media :

[Linkedin](#) • [Twitter](#) • [Facebook](#)